Alector Past Earnings Performance

Past criteria checks 0/6

Alector's earnings have been declining at an average annual rate of -4.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 35.6% per year.

Key information

-4.2%

Earnings growth rate

20.6%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	35.6%
Return on equity	-97.2%
Net Margin	-134.3%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Alector makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:0Z2 Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	97	-130	57
30 Sep 23	96	-141	57
30 Jun 23	102	-143	58
31 Mar 23	126	-135	60
31 Dec 22	134	-133	61
30 Sep 22	133	-136	63
30 Jun 22	301	36	61
31 Mar 22	227	-29	60
31 Dec 21	207	-36	55
30 Sep 21	198	-33	51
30 Jun 21	21	-212	54
31 Mar 21	18	-202	56
31 Dec 20	21	-190	59
30 Sep 20	22	-169	58
30 Jun 20	19	-148	51
31 Mar 20	23	-127	43
31 Dec 19	21	-105	34
30 Sep 19	24	-92	27
30 Jun 19	28	-76	20
31 Mar 19	28	-62	15
31 Dec 18	28	-52	12
30 Sep 18	22	-45	10
30 Jun 18	15	-39	9
31 Mar 18	8	-35	8
31 Dec 17	4	-32	7
31 Dec 16	0	-15	2

Quality Earnings: 0Z2 is currently unprofitable.

Growing Profit Margin: 0Z2 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0Z2 is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Accelerating Growth: Unable to compare 0Z2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0Z2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).

Return on Equity

High ROE: 0Z2 has a negative Return on Equity (-97.19%), as it is currently unprofitable.

Alector Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.62 loss in FY 2022)

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Third quarter 2023 earnings released: US$0.53 loss per share (vs US$0.56 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$0.016 (vs US$0.12 in 2Q 2022)

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings released: US$0.55 loss per share (vs US$0.54 loss in 1Q 2022)

Recent updates

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold €120k worth of stock

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

Full year 2023 earnings released: US$1.56 loss per share (vs US$1.62 loss in FY 2022)

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Insufficient new directors

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold €122k worth of stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Third quarter 2023 earnings released: US$0.53 loss per share (vs US$0.56 loss in 3Q 2022)

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Second quarter 2023 earnings released: EPS: US$0.016 (vs US$0.12 in 2Q 2022)

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

First quarter 2023 earnings released: US$0.55 loss per share (vs US$0.54 loss in 1Q 2022)

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold €89k worth of stock

Key Executive recently sold €79k worth of stock

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$1.56 profit in 3Q 2021)

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Second quarter 2022 earnings released: EPS: US$0.12 (vs US$0.69 loss in 2Q 2021)

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.66 loss in 1Q 2021)

Insufficient new directors

Alector, Inc. Announces Appointment of Gary Romano as Chief Medical Officer

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Forecast breakeven date pushed back to 2023

Alector, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: EPS US$1.56 (vs US$0.67 loss in 3Q 2020)

Insufficient new directors

Alector Announces First Participant Dosed in Phase 2 Study Evaluating Al001 in Amyotrophic Lateral Sclerosis (Als)

Forecast to breakeven in 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.58 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.54 loss in 1Q 2020)

Advisor has left the company

Revenue misses expectations

Full year 2020 earnings released: US$2.45 loss per share (vs US$1.71 loss in FY 2019)

New 90-day high: €16.40

Alector, Inc. Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

Alector, Inc. Announces Executive Changes

New 90-day high: €13.70

New 90-day high: €12.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.67 loss per share

New 90-day low: €8.50

New 90-day low: €9.45

New 90-day low - €10.70

First half earnings released

New 90-day low - €14.50

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta